An Act to repeal 255.056 (7); to renumber and amend 255.056 (3) (c) and 255.056 (3) (d); to amend 255.056 (1) (bg), 255.056 (1) (br), 255.056 (1) (e), 255.056 (2), 255.056 (2m) (intro.), 255.056 (2m) (b), 255.056 (3) (intro.), (a) and (b), 255.056 (4), 255.056 (5), 255.056 (6) (b) and 255.056 (6) (c); to repeal and recreate 255.056 (1) (d) and 255.056 (1) (f); to create 255.056 (1) (bd), 255.056 (1) (bm), 255.056 (1) (br), 255.056 (1) (gc) and (gm), 255.056 (1) (m), 255.056 (2g) (b), 255.056 (2h) (b) and (c), 255.056 (3) (bm), 255.056 (3m) and 255.056 (8) to (20) of the statutes; Relating to: the drug repository program.
SB987 would substantially revise Wisconsin’s drug repository program, which allows donated drugs and supplies to be collected and dispensed to eligible patients. The bill broadens who may donate and receive donated drugs by allowing any person licensed or permitted to possess drugs in the state where they are located to participate, including out-of-state pharmacies, facilities, and other entities. It also expands the types of drugs that may be donated to include prescription drugs, nonprescription drugs, and FDA-approved investigational drugs labeled for investigational use.
The bill shifts many program details from DHS rulemaking into statute. It defines who qualifies as an eligible patient, generally prioritizing indigent, uninsured, underinsured, and public-benefit enrollees, but allowing broader access if no such patient needs the drug. It also sets new requirements for packaging, labeling, storage, temperature control, inspection, recordkeeping, disposal, and substitution, while clarifying that donated drugs may be repackaged and transferred and that participation does not constitute wholesale distribution. The bill repeals a prior subsection and adds extensive new provisions governing program operations, including record retention and cross-state participation.
SB987 would also change the fee structure for donated drugs. It allows recipients to charge handling fees, and for-profit entities may charge up to their cost of providing the drug or supply, with no additional statutory cap beyond those cost-based limits. The bill expressly states that handling, dispensing, and customary charges to patients and other entities do not count as resale, and it preserves immunity from civil and criminal liability for participants except in cases of reckless, wanton, or intentional misconduct.
The bill’s overall effect on state law is to make the drug repository program more detailed, more permissive in some respects, and less dependent on administrative rules. It would amend Wisconsin Statutes section 255.056 extensively, create new definitions and operational standards, and permit participation by entities in other states under certain conditions. It also updates the law to align with federal drug supply chain and returns-processor concepts.
There is no recorded committee transcript or vote detail in the provided materials, so no direct floor or committee sentiment is available. Based on the bill text, the measure appears aimed at expanding access to donated medications and standardizing program administration, but it also introduces operational and fee-related provisions that could draw scrutiny from patient advocates, regulators, pharmacies, and for-profit participants over access, safety, and cost concerns.
SB987 would significantly amend Wisconsin Statutes section 255.056 governing the drug repository program. It would broaden eligible donors and recipients, allow cross-state participation, expand the categories of drugs that may be donated, and replace several DHS rulemaking duties with statutory standards. The bill would also impose detailed requirements for acceptance, storage, repackaging, labeling, substitution, recordkeeping, disposal, and liability protections, while clarifying that participation is voluntary and not wholesale distribution.
No committee discussion or vote record is provided, so there is no documented legislative debate to gauge sentiment. From the bill’s structure and purpose, the measure appears generally supportive of expanding access to donated medications and supplies, with an emphasis on program flexibility and operational clarity. At the same time, the inclusion of for-profit handling fees, cross-state participation, and detailed compliance rules suggests the bill could attract mixed reactions from stakeholders concerned about affordability, safety, and regulatory oversight.
The main points of potential contention are likely to be the bill’s expanded eligibility and participation rules, the allowance for out-of-state entities and a wider range of donors, and the fee provisions for for-profit recipients. Patient advocates may support the broader access provisions but question whether handling fees could raise costs, while regulators and pharmacy stakeholders may focus on safety, storage, repackaging, and recordkeeping burdens. Another possible issue is the bill’s move away from DHS rulemaking toward fixed statutory standards, which may be seen as either providing clarity or limiting administrative flexibility.